Coherus Oncology, Inc.
Coherus Oncology is a commercial-stage oncology company focused on immuno-oncology medicines. It commercializes LOQTORZI, an anti-PD-1 antibody, in the United States for adults with nasopharyngeal carcinoma, both in combination with chemotherapy as a first-line treatment and as monotherapy in later lines. Coherus sells and distributes LOQTORZI in the United States and Puerto Rico through wholesale specialty distributors. It developed the drug in collaboration with Junshi Biosciences and granted Apotex an exclusive license to commercialize it in Canada. The company’s pipeline includes casdozokitug, an investigational antibody targeting IL-27, and tagmokitug, an investigational antibody targeting CCR8. Both are in clinical development, including studies evaluating combinations with LOQTORZI. Coherus has global rights to develop and commercialize these candidates. It also works with contract manufacturers for its commercial product and pipeline drug supply and is moving their biomanufacturing processes to the United States.
No SEC Form 4 filings for $CHRS in the last 30 days.
See all $CHRS insider activity →Coherus Oncology reported interim phase 1b trial results showing tagmokitug, combined with Loqtorzi and chemotherapy, achieved a 75% overall response rate in esophageal cancer patients as a first-line therapy, regardless of PD-L1 status, according to the company.
Coherus Oncology (CHRS) reported interim data for tagmokitug plus toripalimab and chemo in 1L ESCC, showing a confirmed ORR of 75% at cutoff, rising to 89% after two later PRs. The company plans to expand enrollment in 1L and 2L ESCC, with safety deemed acceptable. This data is early-to-mid stage validation for Coherus's CCR8 program.
Coherus Oncology (CHRS) shares rose more than 15% after the company announced a special dividend of contingent value rights (CVRs) tied to monetizing remaining biosimilar assets. CVRs will be distributed pro rata to stockholders of record Sept. 30, 2026, with distribution scheduled for Oct. 7, 2026. Coherus reported Q2 2026 net loss from continuing ops of $33.3M and LOQTORZI revenue up 37% to $13.6M.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CHRS (Coherus Oncology, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent CHRS coverage spans technology, earnings and corporate actions.
Positive early-stage trial results are likely to boost investor sentiment and drive the stock higher.
Positive interim data likely lifts sentiment and may drive short-term buying pressure.
The CVR special dividend is a discrete capital-return event tied to monetization of legacy biosimilar assets, likely supporting near-term sentiment and creating a new valuation overhang around CVR economics.
The 8-K discloses a new secured borrowing framework, which can tighten liquidity and increase default sensitivity via covenants and collateral terms.
The call provides fresh operating and clinical-readout inputs that can reprice CHRS expectations for 2026 revenue trajectory and near-term catalyst timing.
AlphAI scores every news story that mentions CHRS with an AI model for sentiment and relevance, and aggregates insider trades from Coherus Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Coherus Oncology reported interim phase 1b trial results showing tagmokitug, combined with Loqtorzi and chemotherapy, achieved a 75% overall response rate in esophageal cancer patients as a first-line therapy, regardless of PD-L1 status, according to the company.
1 min readCoherus Oncology (CHRS) reported interim data for tagmokitug plus toripalimab and chemo in 1L ESCC, showing a confirmed ORR of 75% at cutoff, rising to 89% after two later PRs. The company plans to expand enrollment in 1L and 2L ESCC, with safety deemed acceptable. This data is early-to-mid stage validation for Coherus's CCR8 program.
1 min readCoherus Oncology (CHRS) shares rose more than 15% after the company announced a special dividend of contingent value rights (CVRs) tied to monetizing remaining biosimilar assets. CVRs will be distributed pro rata to stockholders of record Sept. 30, 2026, with distribution scheduled for Oct. 7, 2026. Coherus reported Q2 2026 net loss from continuing ops of $33.3M and LOQTORZI revenue up 37% to $13.6M.
2 min readCoherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Senior Secured Term Loan On August 12, 2026, Coherus Oncology, Inc. (the “Company”), together with certain wholly owned subsidiaries of the Company (collectively with the Company, the “Borrowers”), entered into a Loan and S
6 min readCoherus Oncology (CHRS) reported Q2 2026 results on an earnings call. LOQTORZI net revenue was $13.6M, up 15% sequentially and 37% YoY. Full-year LOQTORZI guidance is $57M to $62M. Total net revenue from continuing ops was $14.3M. Cash and marketable securities were $105.3M at June 30, 2026.
6 min readCoherus Oncology (NASDAQ:CHRS) reported Q2 updates on tagmokitug and LOQTORZI during an earnings call. It said preliminary head and neck response and biomarker findings are based on limited patients, with formal disclosure expected in October. LOQTORZI net sales were $13.6M, up 15% sequentially. Full-year 2026 LOQTORZI revenue guidance is $57M to $62M; 2026 operating expenses $170M to $175M.
6 min readCoherus Oncology, Inc. (CHRS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update – LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokit
6 min readCoherus Oncology and Zumutor Biologics said they will collaborate on a Phase 1 trial combining ZM008, an NK checkpoint anti-LLT1 antibody, with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor. The study will enroll up to 45 patients in the U.S. across dose-escalation and expansion cohorts for several solid tumors, including CRC, HNSCC, NSCLC, ccRCC and urothelial cancers.
3 min readCoherus Oncology Inc. (NASDAQ: CHRS) is identified as a top penny stock with potential to triple money, following its Q4 2025 earnings report. The company showed progress with increased LOQTORZI sales and significant debt reduction, signaling a transition towards an oncology-focused business. Management anticipates further growth through revenue, partnerships, and clinical catalysts in 2026 for its immunotherapy pipeline.
4 min readDelveInsight's report highlights significant advancements in the Metastatic Hepatocellular Carcinoma (HCC) pipeline, with over 20 companies and 25+ pipeline drugs in development. Key clinical trial updates include Coherus Oncology Inc.'s Phase 2 trial for SRF388 and AstraZeneca's Phase I/II study for AZD5851. The report details several promising emerging drugs like CS1003, Casdozokitug, TTI-101, and ST316, emphasizing the robust research efforts to address this challenging cancer.
3 min read
